Michael D Devous

List of Publications by Year
in descending order

80 papers	4,751 citations	147801 31 h-index	133252 59 g-index
93 all docs	93 docs citations	93 times ranked	5516 citing authors

#	Article	IF	Citations
1	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. Nature Communications, 2022, 13, 1495.	12.8	11
2	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry, 2022, 79, 464.	11.0	47
3	Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nature Medicine, 2021, 27, 871-881.	30.7	354
4	Parametric methods for [^{18}F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 365-373.	4.3	22
5	123I-Iofluopane Single-Photon Emission Computed Tomography as an Imaging Biomarker of Pre-Synaptic Dopaminergic System after Moderate-to-Severe Traumatic Brain Injury. Journal of Neurotrauma, 2020, 37, 2113-2119.	3.4	4
6	Positron Emission Tomography Imaging With [^{18}F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurology, 2020, 77, 829.	9.0	244
7	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. Nature Communications, 2020, 11, 2612.	12.8	283
8	Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. EJNMMI Research, 2020, 10, 65.	2.5	25
9	Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. Journal of Alzheimer's Disease, 2019, 71, 1037-1048.	2.6	22
10	A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 163-170.	2.6	21
11	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. Brain, 2019, 142, 1723-1735.	7.6	156
12	Tau Positron-Emission Tomography in Former National Football League Players. New England Journal of Medicine, 2019, 380, 1716-1725.	27.0	165
13	DT‑01‑05: TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSY‑VALIDATED CASES. Alzheimer's and Dementia, 2019, 15, P1486.	0.8	1
14	Topographic staging of tau positron emission tomography images. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 221-231.	2.4	41
15	Test–Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. Journal of Nuclear Medicine, 2018, 59, 937-943.	5.0	55
16	Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity. Journal of Nuclear Medicine, 2018, 59, 944-951.	5.0	73
17	IC‑P‑216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‑3 TRIAL. Alzheimer's and Dementia, 2018, 14, P177.	0.8	0
18	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer's and Dementia, 2018, 14, 1565-1571.	0.8	98

#	Article	IF	Citations
19	Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 825-837.	6.4	40
20	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	2.6	42
21	Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults. JAMA Neurology, 2017, 74, 830.	9.0	87
22	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain, 2017, 140, aww334.	7.6	257
23	Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimer's and Dementia, 2017, 13, 1117-1124.	0.8	31
24	[18]F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	5.3	148
25	Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 1351-1364.	2.6	48
26	Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dementia and Geriatric Cognitive Disorders, 2017, 44, 129-143.	1.5	35
27	[IC‐01‐04]: A ROBUST, SIMPLIFIED BRAAK‐TYPE CLASSIFICATION SCHEME FOR FLORTAUCIPIR F‐18 TAU PET IMAGES. Alzheimer's and Dementia, 2017, 13, P3.	0.8	0
28	[P2‐383]: COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER's DISEASE PATHOLOGY: A PILOT CLINICO‐PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P776.	0.8	1
29	[P4‐227]: THE ASSOCIATION OF TAU BURDEN IN CEREBRAL LOBES AND FUNCTIONAL BRAIN NETWORKS WITH PERFORMANCE IN DIFFERENT COGNITIVE DOMAINS. Alzheimer's and Dementia, 2017, 13, P1357.	0.8	0
30	[P4‐235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.8	0
31	[O5‐01‐01]: PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD. Alzheimer's and Dementia, 2017, 13, P1452.	0.8	3
32	[P4‐530]: MODELING OF TAU TRAJECTORIES ACROSS THE ALZHEIMER's DISEASE SPECTRUM USING [18F]‐FLORTAUCIPIR PET IMAGING. Alzheimer's and Dementia, 2017, 13, P1552.	0.8	0
33	IC‐P‐196: Quantification of TAU Load Using [18F]AV‐1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.8	0
34	O4‐02‐05: The Relationship of [18F]Av‐1451 Pet Tau Images to Changes in Cognition Over Time. Alzheimer's and Dementia, 2016, 12, P336.	0.8	0
35	IC‐P‐022: Conversion of Amyloid Quantitation With Florbetapir Suvr to The Centiloid Scale. Alzheimer's and Dementia, 2016, 12, P25.	0.8	6
36	IC-P-134: Differentiating Preclinical Alzheimer's Disease from Normal Aging: The Effects of Age and Amyloid on Cognitive Decline Over 3.5 Years. , 2016, 12, P100-P100.		0

#	Article	IF	Citations
37	O1‑07‑02: Image Patterns and Clinical Phenotypes Associated with Fastest Increase of TAU Burden Measured by Longitudinal [18F]‑AV‑1451 (T807) PET Studies. Alzheimer's and Dementia, 2016, 12, P189.	0.8	0
38	O4-07-01: Evolution of [18 F]Av-1451 Pet Tau Signal: Interim Analysis of an 18-Month Phase 2 Study. , 2016, 12, P347-P347.		0
39	O4‑08‑06: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F‑18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β‑AMYLOID PLAQUE‑SPECIFIC ANTIBODY, IN ALZHEIMER'S DISEASE (AD). Alzheimer's and Dementia, 2016, 12, P352.	0.8	19
40	Regional profiles of the candidate tau PET ligand ^{18}F-AV-1451 recapitulate key features of Braak histopathological stages. Brain, 2016, 139, 1539-1550.	7.6	372
41	Dopamine efflux in response to ultraviolet radiation in addicted sunbed users. Psychiatry Research - Neuroimaging, 2016, 251, 7-14.	1.8	62
42	Amyloid deposition in younger adults is linked to episodic memory performance. Neurology, 2016, 87, 2562-2566.	1.1	27
43	Successful classification of cocaine dependence using brain imaging: a generalizable machine learning approach. BMC Bioinformatics, 2016, 17, 357.	2.6	34
44	Kinetics of the Tau PET Tracer ^{18}F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 1535-1542.	5.0	84
45	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 4.	6.2	134
46	IC-P-030: Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials. , 2015, 11, P29-P30.		0
47	P4-259: Relationships between cognitive assessments and spatial distribution of neuropathological tau as assessed by 18 F AV-1451 PET scanning. , 2015, 11, P881-P881.		0
48	O1‑07‑06: Hippocampal sparing and limbic predominant tau subtypes of Alzheimer's disease determined *in vivo* using [18F]‑AV‑1451 PET imaging. Alzheimer's and Dementia, 2015, 11, P144.	0.8	2
49	The effect of beta‑amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signal. Human Brain Mapping, 2015, 36, 2514-2526.	3.6	25
50	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 412-419.	2.4	80
51	IC-P-165: Understanding the topology of 18 F-AV-1451 (also known as T807) PET tau images in Alzheimer's disease. , 2015, 11, P110-P111.		0
52	IC-P-171: Region-dependent kinetics of the Tau PET tracer [18 F]-AV-1451 (T807). , 2015, 11, P113-P113.		1
53	DT-02-03: A randomized, controlled, multicenter, international study of the impact of florbetapir (18) Tj ETQq1 1 0.784314 rgBT /Over		
54	Quantification of 18F-florbetapir PET: comparison of two analysis methods. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 725-732.	6.4	25

#	Article	IF	Citations
55	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's and Dementia, 2015, 11, 1.	0.8	603
56	Interaction between early life stress and alcohol dependence on neural stress reactivity. Addiction Biology, 2015, 20, 523-533.	2.6	17
57	A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. Journal of Nuclear Medicine, 2015, 56, 1736-1741.	5.0	61
58	Technical Considerations in Brain Amyloid PET Imaging with ¹⁸F-Florbetapir. Journal of Nuclear Medicine Technology, 2015, 43, 175-184.	0.8	26
59	Cortico-Amygdala Coupling as a Marker of Early Relapse Risk in Cocaine-Addicted Individuals. Frontiers in Psychiatry, 2014, 5, 16.	2.6	63
60	Differences in regional cerebral blood flow response to a 5HT3 antagonist in earlyâ€•and lateâ€•onset cocaineâ€•dependent subjects. Addiction Biology, 2014, 19, 250-261.	2.6	5
61	O1-07-05: IMPACT OF B-AMYLOID BURDEN ON BRAIN PERFUSION AND VASCULAR REACTIVITY IN NORMAL AGING. , 2014, 10, P143-P144.		1
62	P4-136: DOES HIPPOCAMPAL VOLUME PREDICT POSITIVE AMYLOID STATUS ON FLORBETAPIR-PET IN HEALTHY CONTROLS AND PRODROMAL STAGES OF ALZHEIMER'S DISEASE?. , 2014, 10, P836-P837.		0
63	ICâ€•Pâ€•183: EMPLOYING EARLY UPTAKE DATA FROM F18â€•FLORBETAPIR SCANS AS AN ESTIMATE OF REGIONAL CEREBRAL BLOOD FLOW: COMPARISON TO F18â€•FDG. Alzheimer's and Dementia, 2014, 10, P102.	0.8	5
64	P4-311: IS FLORBETAPIR-PET OCCIPITAL SUVR A LATE BIOMARKER IN MILD OR MODERATE AD DEMENTIA AS COMPARED TO HIPPOCAMPAL VOLUME?. , 2014, 10, P900-P900.		0
65	IC-01-02: AMYLOID ACCUMULATION IN EARLY AND MIDDLE ADULTHOOD: THE IMPACT OF LIFE EXPERIENCE. , 2014, 10, P1-P1.		0
66	P4-306: EFFECTS OF IN VIVO AMYLOID BURDEN ON COGNITION IN HEALTHY ADULTS AGED 30 TO 89: INITIAL LONGITUDINAL RESULTS ACROSS 3.5 YEARS FROM THE DALLAS LIFESPAN BRAIN STUDY. , 2014, 10, P897-P898.		0
67	P4-314: TEST-RETEST DATA FOR THE TAU PET IMAGING AGENT 18F-AV-1451 (PREVIOUSLY, 18F-T807). , 2014, 10, P901-P901.		2
68	P4-316: MEASURING CHANGE IN BETA-AMYLOID BURDEN OVER TIME USING FLORBETAPIR-PET AND A SUBCORTICAL WHITE MATTER REFERENCE REGION. , 2014, 10, P902-P902.		8
69	Risk factors for mild cognitive impairment among Mexican Americans. Alzheimer's and Dementia, 2013, 9, 622.	0.8	79
70	IC-O3-01: The Centiloid Scale: Standardization of amyloid imaging measures. , 2013, 9, P8-P8.		4
71	Risk Factors for Î²-Amyloid Deposition in Healthy Aging. JAMA Neurology, 2013, 70, 600.	9.0	216
72	Altered Neural Processing of Threat in Alcohol-Dependent Men. Alcoholism: Clinical and Experimental Research, 2013, 37, 2029-2038.	2.4	23

#	Article	IF	Citations
73	Biomarkers of Alzheimer's Disease Among Mexican Americans. Journal of Alzheimer's Disease, 2013, 34, 841-849.	2.6	69
74	The Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans. Journal of Alzheimer's Disease, 2013, 34, 701-706.	2.6	45
75	Striatal–limbic activation is associated with intensity of anticipatory anxiety. Psychiatry Research - Neuroimaging, 2012, 204, 123-131.	1.8	17
76	Distinctive disruption patterns of white matter tracts in Alzheimer's disease with full diffusion tensor characterization. Neurobiology of Aging, 2012, 33, 2029-2045.	3.1	104
77	Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. NeuroImage, 2012, 62, 1-8.	4.2	84
78	Characterization of Mexican Americans with Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 373-379.	2.6	90
79	Caudolateral orbitofrontal regional cerebral blood flow is decreased in abstinent cocaine‐addicted subjects in two separate cohorts. Addiction Biology, 2012, 17, 1001-1012.	2.6	11
80	Comparison of relative cerebral blood flow maps using pseudo‐continuous arterial spin labeling and single photon emission computed tomography. NMR in Biomedicine, 2012, 25, 779-786.	2.8	25